FXa takes center stage in vascular inflammation

Abstract

In this issue of Blood, Sparkenbaugh et al identify coagulation factor Xa (FXa), the target for new protease-selective oral anticoagulants, as a crucial mediator for both coagulation abnormalities and chronic vascular inflammation that characterize sickle cell disease.1 © 2014 by The American Society of Hematology.